Newsletter Subscription

Enter Name and Email

06 August 2010 - Just published: Central 5-HT2B antagonists control dopamine release

A new study examines the CNS activity of serotonin 5-HT2B receptors. Indeed, antipsychotics such as clozapine and aripiprazole, and some antidepressants, such as agomelatine, act as antagonists at this site. This new study demonstrates that, in rat, selective 5-HT2B receptor antagonists inhibit dopamine release in nucleus accumbens, notably when this is stimulated by the psychotomimetic agent, amphetamine. Further, 5-HT2B antagonism opposes amphetamine-induced hyperlocomotion. These data suggest that 5-HT2B receptor antagonism may have utility in treating psychosis and/or mood disorders.
For more information, Contact.


The central serotonin2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity.

Auclair AL, Cathala A, Sarrazin F, Depoortère R, Vincenzo Piazza P, Newman-Tancredi A, Spampinato U.
J Neurochem. 2010 Sep 1;114(5):1323-32. Epub 2010 Jun 7